Abstracts tagged "dermatomyositis and interferons"

Abstract Number: 876 • 2018 ACR/ARHP Annual Meeting
Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease
Tori Nault¹, Alex Tsoi², Tamra J. Reed³, Mehrnaz Gharaee-Kermani³, Lori Lowe⁴, Johann Gudjonsson⁴ and Michelle Kahlenberg³, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Dermatomyositis (DM) is a rare disease with both cutaneous and muscle pathophysiology. In the skin of DM patients, very little is known about the…
Abstract Number: 944 • 2015 ACR/ARHP Annual Meeting
Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features
Hayley W. Leatham¹, Kerri Rieger², Lorinda Chung³, Shufeng Li¹, Brandon W. Higgs⁴, Yihong Yao⁴, Kavita Sarin¹ and David Fiorentino¹, ¹Dermatology, Stanford University, Stanford, CA, ²Dermatopathology, Stanford University, Stanford, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose :Interferon (IFN) signaling is upregulated in dermatomyositis (DM) skin, but the relationship to classic histopathologic features is unknown. Methods :Thirty-nine skin biopsies from patients…
Abstract Number: 1037 • 2014 ACR/ARHP Annual Meeting
Anti-MDA5 Antibody Associated Myositis Compared to DM Patient: A Distinct Muscular Pattern Associated with a shared IFN Signature
Yves Allenbach^1,2,3, Gaelle Leroux⁴, Aude Rigolet², Baptiste Hervier⁵, Nicolas Limal⁶, Peter Hufnagl⁷, Norman Zerbe⁸, Thierry Maisonobe⁹, Alain Meyer¹⁰, Yurdagul Uzunhan¹¹, Kuberaka Mariampillai¹², Romain Gherardi¹³, Serge Herson¹², Olivier Benveniste^2,3 and Werner Stenzel¹⁴, ¹Neuropathology, Charite Hospital, Berlin, Germany, ²Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ³UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁵Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ⁷Pathology departmen, Charite Hospital, Berlin, Germany, ⁸Department of Pathology, Charite Hospital, Berlin, Germany, ⁹Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Pneumology, APHP Avicenne Hospital, Bobigny, France, ¹²Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ¹³Pathology, APHP Henri Mondor Hospital, Creteil, France, ¹⁴Department of Neuropathology, Charite Hospital, Berlin, Germany
Background/Purpose Anti-MDA5 auto-antibodies are thought to be specifically associated with dermatomyositis (DM). Nevertheless anti-MDA5 auto-antibody positive patients (MDA5+ DM) predominantly suffer from extra-muscular involvement with severe…
Abstract Number: 2079 • 2013 ACR/ARHP Annual Meeting
Serum Interferon α, β and Interleukin-18 Are Associated With Disease Activity Of Rapidly Progressive Interstitial Lung Disease In Patients With Clinical Amyopathic Dermatomyositis
Shinji Sato¹, Noriko Sasaki¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: It is well known that rapidly progressive interstitial lung disease (RP-ILD) in patients with dermatomyositis (DM) is associated with poor outcome. Previous findings suggested…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].